Alector Inc
For the period ended Dec 31, 2023. Filed Feb 27, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 27, 2024
ALEC$2.53+2.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
Consolidated Statem ents of Cash Flows
(In thousands)
| Year Ended December 31, | |||
|---|---|---|---|
| 2023 | 2022 | 2021 | |
| Cash flows from operating activities: | |||
| Net loss | $(130,391) | $(133,310) | $(36,329) |
| Adjustments to reconcile net loss to net cash used in operating activities: | |||
| Depreciation and amortization | 5,725 | 5,714 | 6,329 |
| Stock-based compensation | 42,798 | 46,146 | 40,785 |
| Amortization of premiums and accretion of discounts on marketable securities | (15,318) | (1,163) | 2,099 |
| Amortization of right-of-use assets | 3,123 | 2,758 | 1,986 |
| Loss from disposal of fixed assets | 48 | — | — |
| Changes in operating assets and liabilities: | |||
| Receivable from collaboration partner | 2,587 | 4,804 | (7,391) |
| Prepaid expenses and other current assets | (5,949) | (3,926) | 1,132 |
| Other assets | (1,009) | (835) | (2,957) |
| Accounts payable | (377) | (572) | 1,917 |
| Accrued liabilities and accrued clinical supply costs | 2,546 | (2,655) | 2,391 |
| Payable to collaboration partner | 7,703 | — | — |
| Deferred revenue | (66,782) | 66,383 | 292,915 |
| Refund liability to collaboration partner | (24,512) | — | — |
| Lease liabilities | (4,968) | (4,274) | (4,012) |
| Other long-term liabilities | 614 | 601 | (314) |
| Net cash provided by (used in) operating activities | (184,162) | (20,329) | 298,551 |
| Cash flows from investing activities: | |||
| Purchase of property and equipment | (2,381) | (4,117) | (3,247) |
| Purchase of marketable securities | (551,729) | (556,898) | (343,402) |
| Maturities of marketable securities | 652,523 | 402,001 | 286,290 |
| Sale of marketable securities | 3,505 | — | 10,696 |
| Net cash provided by (used in) investing activities | 101,918 | (159,014) | (49,663) |
| Cash flows from financing activities: | |||
| Proceeds from the exercise of options to purchase common stock | 1,079 | 3,059 | 28,530 |
| Proceeds from issuance of stock from employee stock purchase plan | 1,471 | 1,455 | 1,765 |
| Net cash provided by financing activities | 2,550 | 4,514 | 30,295 |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | (79,694) | (174,829) | 279,183 |
| Cash, cash equivalents, and restricted cash at beginning of period | 155,795 | 330,624 | 51,441 |
| Cash, cash equivalents, and restricted cash at end of period | 76,101 | $155,795 | $330,624 |
| Non-cash investing and financing activities: | |||
| Property and equipment purchases included in accounts payable and accrued liabilities | $172 | $493 | $705 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.